>

Satellite Symposium


  • September 2 (THU)
  • September 3 (FRI)

Satellite Symposium 1
pfizer

From science to Real-world data(RWD) with breast cancer patient
Date & Time Sep. 2 (Thu), 09:00-09:40 Venue Room D
Chair In Hae PARK (Korea University Guro Hospital, Korea)
Speaker
  1. 1.Sharing experiences of HR+/HER2- mBC patients based on Real-World Evidence & practice
    Yeon Hee PARK (Samsung Medical Center, Korea)
  2. 2.The molecular etiology of luminal breast cancer
    Matthew James Clifford ELLIS (Baylor College of Medicine, USA)

Satellite Symposium 2
Servier

Management of mPaCa patients: Focused on Liposomal Irinotecan(ONIVYDE)
Date & Time Sep. 2 (Thu), 09:50-10:30 Venue Room D
Chair Myung Ah LEE (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
Speaker
  1. Management of mPaCa patients: Focused on Liposomal Irinotecan(ONIVYDE)
    Choong-Kun LEE (Yonsei Cancer Center, Korea)

Satellite Symposium 3
MSD

The welcome rain, Pembrolizumab: New hope for MSI-H/dMMR colorectal cancer patients
Date & Time Sep. 2 (Thu), 12:40-13:20 Venue Room C
Chair Tae-You KIM (Seoul National University Hospital, Korea)
Speaker
  1. The welcome rain, Pembrolizumab: New hope for MSI-H/dMMR colorectal cancer patients
    Soohyeon LEE (Korea University Anam Hospital, Korea)

Satellite Symposium 4
Eisai

The evolving HCC treatment landscape: What is the role of LENVIMA
Date & Time Sep. 2 (Thu), 13:30-14:10 Venue Room C
Chair Baek-Yeol Ryoo (Asan Medical Center, Korea)
Speaker
  1. 1.The evolving HCC treatment landscape: What is the role of LENVIMA?
    Arndt VOGEL (Hannover Medical School, Germany)
  2. 2.Exploring real world experience of Lenvatinib: What can we expect in the future?
    Jaekyung CHEON (CHA Bundang Medical Center, Korea)

Satellite Symposium 5
Jeil

TAS-102, New therapeutic option for patients with CRC / GC
Date & Time Sep. 2 (Thu), 13:30-14:10 Venue Room D
Chair Yeul Hong KIM (Korea University Anam Hospital, Korea)
Speaker
  1. 1.Optimal treatment for metastatic Colorectal cancer: The new role of TAS-102
    Dong-Hoe KOO (Kangbuk Samsung Hospital, Korea)
  2. 2.Optimal treatment for metastatic gastric cancer: The new role of TAS-102
    Wonyoung CHOI (National Cancer Center, Korea)

Satellite Symposium 6
Ipsen

Shifting perception in treatment of advanced renal cell carcinoma
Date & Time Sep. 2 (Thu), 15:50-16:30 Venue Room D
Chair Jae Lyun LEE (Asan Medical Center, Korea)
Speaker
  1. 1.What is today’s understanding of the treatment landscape for advanced RCC?
    Chan KIM (CHA Bundang Medical Center, Korea)
  2. 2.How to navigate among multiple options with Cabozantinib in aRCC?
    In-Ho KIM (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)

Satellite Symposium 7
Norvartis

Evolving treatment landscape with CDK 4/6 inhibitors in metastatic breast cancer
Date & Time Sep. 2 (Thu), 16:40-17:20 Venue Room D
Chair Kyung Hae JUNG (Asan Medical Center, Korea)
Speaker Are all CDK4/6 inhibitors the same?
Kyung-Hun LEE (Seoul National University Hospital, Korea)

Satellite Symposium 8
takeda

The evolving ALK+ NSCLC paradigm: The future of 1st line and beyond
Date & Time Sep. 3 (Fri), 10:00-10:40 Venue Room D
Chair Dae Ho LEE (Asan Medical Center, Korea)
Speaker
  1. The evolving ALK+ NSCLC paradigm: The future of 1st line and beyond
    David Ross CAMIDGE (UCHealth Lung Cancer Clinic - Anschutz Medical Campus, USA)

Satellite Symposium 9
MSD

KEYTRUDA® for 1L TNBC – A new hope that blooms in the wild land.
Date & Time Sep. 3 (Fri), 10:50-11:20 Venue Room D
Chair Seock-Ah IM (Seoul National University Hospital, Korea)
Speaker
  1. KEYTRUDA® for 1L TNBC – A new hope that blooms in the wild land
    Rita NANDA (UChicago Medicine, USA)

Satellite Symposium 10
innoN

Optimal treatment strategy in metastatic colorectal cancer
Date & Time Sep. 3 (Fri), 12:40-13:20 Venue Room D
Chair Joong Bae AHN (Yonsei Cancer Center, Korea)
Speaker
  1. Exploring better combinations for 1st line treatment in mCRC
    Seung-Hoon BEOM (Yonsei Cancer Center, Korea)

Satellite Symposium 11
Yuhan

From clinical trials to practice: New era of EGFRm NSCLC treatment, LECLAZA®
Date & Time Sep. 3 (Fri), 13:20-14:00 Venue Room D
Chair Jin-Hyoung KANG (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)
Speaker
  1. From clinical trials to practice: New era of EGFRm NSCLC treatment, LECLAZA®
    Myung-Ju Ahn (Samsung Medical Center, Korea)

Satellite Symposium 12
Sanofi

What is being considered for treatment decision for 2nd line mCRC?
Date & Time Sep. 3 (Fri), 14:20-15:00 Venue Room D
Chair Dae Young ZANG (Hallym University Sacred Heart Hospital, Korea)
Speaker
  1. 1.Optimal choice of the second line mCRC treatment based on experience
    Soohyeon LEE (Korea University Anam Hospital, Korea)
  2. 2.Treatment decision for second line mCRC using the insights from biomarker data
    Jeong Eun KIM (Asan Medical Center, Korea)

Satellite Symposium 13
Amgen

Optimal bone health management with BTA in bone metastatic solid tumor
Date & Time Sep. 3 (Fri), 15:10-15:50 Venue Room D
Chair Kyung hee LEE (Yeungnam University Medical Center, Korea)
Speaker
  1. 1.Multidisciplinary treatment for bone metastatic breast cancer
    Jin-Hee AHN (Asan Medical Center, Korea)
  2. 2.Bone health management in prostate cancer
    Yoon Ji CHOI (Korea University Anam Hospital, Korea)